30 likes | 41 Views
Migraine Drugs Market Research Report - Global Forecast till 2025<br>
E N D
Migraine Medications Market Worth of 6.5 Billion USD by 2025 | Major Market Players Share Players Share Analysis Analysis, Regional Growth , Regional Growth, , Rising Demand and Opportunit Opportunities ies Major Market Rising Demand and Business Business The Global Migraine Medications Market is expected to hold a value of USD 6.5 Billion by 2025 at a CAGR of 5.9%. Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. The growth of the global Migraine Medications Market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine. Some of the key players in the global Migraine Medications Market are Allergan Plc (Ireland) Alder Biopharmaceuticals Inc. (US) Pfizer Inc. (US) GlaxoSmithKline Plc (UK) Merck & Co. Inc. (US) Teva Pharmaceutical Industries Ltd (Israel) AstraZeneca Plc (UK) Johnson & Johnson Services Inc. (US) Amgen Inc (US) Eli Lilly and Company eNeura Inc and Others Get a Free Sample PDR @https://www.marketresearchfuture.com/sample_request/8379 Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain. Market Segmentation | Market Research Future |
The global Migraine Medications Market has been segmented based on type, treatment, drug class, and end user. The global Migraine Medications Market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine. The global Migraine Medications Market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others. The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine. The global Migraine Medications Market has been segmented, on the basis of drug class, into beta- blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others. LIST OF TABLES TABLE 1 GLOBAL MIGRAINE MEDICATIONS MARKET SYNOPSIS, 2019–2025 TABLE 2 GLOBAL MIGRAINE MEDICATIONS MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION) TABLE 3 GLOBAL MIGRAINE MEDICATIONS MARKET, BY TREATMENT TYPE, 2019–2025 (USD MILLION) TABLE 4 GLOBAL MIGRAINE MEDICATIONS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION) TABLE 5 GLOBAL MIGRAINE MEDICATIONS MARKET, BY END USER, 2019-2025 (USD MILLION) TABLE 6 GLOBAL MIGRAINE MEDICATIONS MARKET, BY REGION, 2019–2025 (USD MILLION) …Continued Browse https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379 Complete Premium Report Details @ LIST OF FIGURES FIGURE 1 RESEARCH PROCESS FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MIGRAINE MEDICATIONS MARKET FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MIGRAINE MEDICATIONS MARKET FIGURE 4 GLOBAL MIGRAINE MEDICATIONS MARKET SHARE, BY TREATMENT TYPE, 2018 (%) FIGURE 5 GLOBAL MIGRAINE MEDICATIONS MARKET SHARE, BY DRUG CLASS, 2018 (%) FIGURE 6 GLOBAL MIGRAINE MEDICATIONS MARKET SHARE, BY END USER, 2018(%) FIGURE 7 GLOBAL MIGRAINE MEDICATIONS MARKET SHARE, BY REGION, 2018 (%) …To be Continued Regional Analysis | Market Research Future |
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The Migraine Medications Market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. Get More Details OR Any Query Feel FREE To Contact@ https://www.marketresearchfuture.com/enquiry/8379 About Market Research Future: Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. Contact: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India +1 646 845 9312 Email: sales@marketresearchfuture.com | Market Research Future |